Semaglutide, through its action on the GLP-1 receptors, not only assists in weight reduction by regulating appetite and food intake but also shows promise in sustaining weight loss over extended periods when combined with lifestyle modifications like diet and exercise
Important considerations when restarting include: Resume at your usual maintenance dose unless otherwise advised by your prescriber Be aware that you may experience temporary changes in appetite or gastrointestinal symptoms as the medication re-establishes its effects Monitor for any unusual symptoms, particularly if therapeutic interventions were performed Maintain adequate hydration, especially in the first few days after resuming treatment If you experience persistent abdominal pain, rectal bleeding, fever, or severe nausea after resuming Wegovy following colonoscopy, contact your GP or the endoscopy unit immediately
The majority were also able to stop taking basal insulin altogether
If you are not losing weight on semaglutide and the timing correlates with a questionable shipment, the medication may be compromised
It enhances the secretion of insulin in a glucose-dependent manner (meaning it releases insulin only when blood sugar is high), and it suppresses glucagon release
